We hypothesized that non-proliferating (quiescent) human vascular endothelial cells would not express somatostatin receptor subtype 2 (sst 2) and that this receptor would be expressed when the endothelial cells begin to grow. To test this hypothesis, placental veins were harvested from 6 human placentas and 2 mm vein disks were cultured in 0.3% fibrin gels. Morphometric analysis confirmed that 50-75% of cultured vein disks developed radial capillary growth within 15 days. Sst 2 gene expression was determined by reverse transcription-polymerase chain reaction (RT-PCR) analysis of the RNA from veins before culture and from tissue-matched vein disks that exhibited an angiogenic response. The sst 2 gene was expressed in the proliferating angiogenic sprouts of human vascular endothelium. The presence of sst 2 receptors on proliferating angiogenic vessels was confirmed by immunohistochemical staining and in vivo scintigraphy. These results suggest that sst 2 may be a unique target for antiangiogenic therapy with sst 2 preferring somatostatin analogues conjugated to radioisotopes or cytotoxic agents.
Angiogenesis is a tightly regulated process that normally occurs during embryonic development and is suppressed in adult life. We have previously demonstrated that somatostatin (SRIF) analogues will inhibit angiogenesis in the chicken chorioallantoic membrane (CAM) and in the rabbit corneal micropocket models (Woltering et al, 1991; Patel et al, 1994; Barrie et al, 1993; Conway et al, 1996) . These observations have been confirmed by Danesi et al, who demonstrated that somatostatin analogues will inhibit angiogenesis in the CAM model and will inhibit the proliferation of human umbilical vein endothelial cells (HUVECs) in culture (Danesi et al, 1997) . In our previous studies, we demonstrated that SRIF-induced inhibition of angiogenesis in the CAM is G-proteinadenylate cylase-, and calcium-dependent (Patel et al, 1994) . We have also shown that the ability of a somatostatin analogue to inhibit angiogenesis is proportional to its sst 2-binding affinity and its ability to inhibit growth hormone release, a sst 2-dependent process (Woltering et al, 1997) . These observations imply that endothelial cells growing from human blood vessels express sst 2. External scintigraphic scanning with the sst 2-preferring analogue, 111 In-pentetreotide, has demonstrated binding to cells in malignant tissue and to cells in non-malignant tissue in which angiogenesis is occurring but not to normal blood vessels. Similarly, van Hagen et al demonstrated that 111 In-pentetreotide localizes to active rheumatoid joints but not to osteoarthritic joints (van Hagen et al, 1994) . These authors postulated that the radiolabelled somatostatin analogue binds to the vascular pannus in active rheumatoid joints but does not bind to cells in non-vascularized, normal or osteoarthritic joints (van Hagen et al, 1994) . Reubi et al, using autoradiographic techniques have demonstrated that proliferating human peritumoral vessels bind 125 I-tyr 3 -octreotide, a sst 2-preferring radioligand, while distant quiescent vessels do not (Reubi et al, , 1996 Denzler and Reubi, 1999) .
Based on these observations, we hypothesized that nonproliferating human vascular endothelial cells do not express sst 2 but these receptors are expressed when endothelial cells proliferate. To test this hypothesis, normal placental veins were harvested from 6 human placentas obtained immediately following delivery. RNA was harvested from quiescent (native) placental vessels and from vessel fragments which had been cultured in vitro. In this culture system, we have investigated changes in gene expression as vascular endothelial cells begin to sprout, migrate, and proliferate (Watson et al, 1996) . Previous work in our laboratories using this culture system revealed that the gene for a vascular endothelial growth factor (VEGF) receptor, kdr, is expressed in angiogenic vein disks but not in placental vessels in which endothelial growth is not occurring.
METHODS

In vitro culture of human placental veins
Fresh human placentas were obtained from 6 anonymous donors following guidelines established by the LSU Institutional Review Board, Protocol #2828. Placental veins were trimmed of surrounding tissue, opened longitudinally and 2 mm diameter disks prepared using a sterile skin biopsy punch. Residual placental vein tissue was placed in Ultraspec® RNA isolation solution (Biotex, Inc, Houston, TX) for subsequent RNA extraction. Vein disks (N = 100/assay) were incorporated into 0.3% fibrin gels in complete tissue culture medium containing 20% fetal Growing vascular endothelial cells express somatostatin subtype 2 receptors bovine serum (FBS), ε-amino caproic acid, antibiotics and antifungals. Fibrin gels were overlaid with tissue culture medium consisting of minimal essential medium (MEM, Gibco, Grand Island, NY), supplemented with 10% FBS, penicillin, streptomycin and Fungizone according to methods outlined by Watson et al and Brown et al (Brown et al, 1996; Watson et al, 1996) . Culture plates were incubated in a 5% CO 2 /95% air atmosphere at 37°C for 15 days and observed daily with an inverted microscope. At 15 days, cultures exhibiting endothelial cell growth and those not exhibiting an angiogenic response were collected for RNA isolation. Separate experiments with cultured, nonangiogenic vein disks were performed to determine if their failure to proliferate was due to poor cell viability. The MTT cell viability assay (Promega Corporation, Madison, WI) confirmed that these disks contained viable cells even though they did not exhibit an angiogenic response.
Reverse transcription-polymerase chain reaction (RT-PCR) analysis of gene expression
Venous tissue collected at the time of preparation of the disks, cultured disks that did not develop endothelial sprouts and disks which developed sprouts were collected in separate RNase-free tubes and homogenized in an RNA isolation solution (RNAzol, Biotex, Houston, TX). RNA from each sample was quantitated by A 260 /A 280 spectrophotometric analysis. 500 ng of RNA was reverse transcribed in the presence of random hexamer primers using a reverse transcription system (Perkin-Elmer Applied Biosystems, Carson City, CA). The expression of the sst 2 gene and the constitutively expressed gene for glyceraldehyde-6-phosphodehydrogenase (GAPDH) was determined by amplifying the cDNAs from non-proliferating and from proliferating placental endothelial cells. Following 35 amplification cycles, the gene products were analysed on 2% agarose gels stained with ethidium bromide. Visualization of the amplified gene products was performed with an Eagle-EyeII® gel documentation system (Stratagene, Inc, La Jolla, CA) ( Figure 1 ). Nucleotide sequences of the primers and probes used are given in Table 1 .
Southern hybridization
Southern hybridization was used to confirm the identity of the amplified gene products. DNA probes, complementary to an internal sequence of the amplified sst 2 and GAPDH amplicons (Table 1) , were labelled with biotin (Ready-To-Go beads, Pharmacia Biotech, Piscataway, NJ). 10 mg of labelled probe in Express Hyb® hybridization solution was incubated with nitrocellulose membranes (Tropilon Plus, Tropix Inc, Bedford, MA) to which were bound the amplified products. The hybridized biotinlabelled probes were detected using the Southern-Light® detection system (Tropix). Autoradiography was performed on X-ray film (X-OMAT AR, Kodak Corp., Rochester, NY).
Localization of radiolabelled somatostatin analogues in angiogenic vessels in vivo
Nude mice (Harlan Sprague Dawley, Indianapolis, IN) were injected in the hindquarter with 1 × 10 6 SKNSH human neuroblastoma tumour cells, in accordance with LSUHSC Institutional Animal Care and Use Committee approved Protocol #1806. SKNSH cells do not express sst 2 as measured by both RT-PCR and in vitro binding assays . Injection sites were observed for 2-3 months until tumours grew to 2 cm in diameter. Mice were injected in the tail vein with 3 mCi of 125 I-WOC4a[DTyr-Tyr-Tyr-DTyr-Cys-Phe-DTrp-Lys-Thr-CysThr], an sst 2-preferring somatostatin analogue . We have previously shown that this radioiodinated analogue has a high binding affinity for sst 2 (Kd~1nM) and will induce receptor-specific cytotoxicity in human (IMR32) neuroblastoma cells (Meyers et al, 1998) . Background counts were allowed to clear for 5 days, and the mice were then scanned and radiographed. Because of the low energy emissions of 125 I, mice were scanned on both their ventral and dorsal surfaces.
Preparation of sst 2 antiserum
An oligonucleotide corresponding to the N terminal 45 amino acids of sst 2 was cloned into pET-32a(+) vector (Norvagen, Madison, WI) as a C terminal fusion to thioredoxin using T4DNA ligase (TA cloning kit, Invitrogen, Carlsbad, CA). The resulting plasmid was sequenced in order to confirm that the insert was in the correct orientation and that the sequence matched the native gene sequence. The plasmid was transformed into the AD494 bacterial host strain (Novagen, Madison, WI) and plated on LB plates containing ampicillin and kanamycin overnight at 37°C. Colonies were picked and cultured in 20 ml LB medium (containing 100 µg ml -1 ampicillin and 30 µg ml -1 kanamycin) overnight at 37°C in a shaking incubator. Bacterial cultures were diluted 1:50 with fresh medium and cultured 3 to 4 hours until the O.D. at 600 nm was greater than 0.6. Isopropylthio-β-D-galactosidase (IPTG) was added to a final concentration of 1 mM to induce protein expression. After 2 hours bacteria were collected by centrifugation at 8000 g for 10 minutes. The pellets were resuspended in start buffer (1 × PBS and 10 Mm imidazole, pH 7.4) and sonicated using a Polytron® at setting 7 with 5 second bursts for 1 minute to release the sst 2 peptide. Supernatants were collected and pellets sonicated again. The sst 2-containing supernatant was filtered through a 0.45 µm filter (Nalgene, Rochester, NY) and the protein concentration was determined. The peptide was purified using the Pharmacia His Trap® column system (Amersham Pharmacia Biotech, Piscataway, NJ), dialysed against a 0.9% NaCl solution overnight at 4°C, and concentrated using a Centriplus® concentrator (Amicon, Beverly, MA).
3 kg male rabbits were immunized with 500 µg sst 2 peptide in 0.5 ml 0.9% NaCl emulsified with an equal volume of Freund's complete adjuvant. The emulsion was injected both intramuscularly and intradermally. Four booster injections (100 µg peptide) were given at 3-week intervals. Serum was collected before each booster injection and 3 weeks after the final injection and stored at -20°C. This antibody has been previously characterized by Balster et al (2001) and Albers et al (2000) .
Immunohistochemical staining
Placental vein disks were cultured in 48-well plate membranebottomed inserts. Disks which visually exhibited an angiogenic response were fixed in 10% neutral-buffered formalin and embedded in paraffin using standard tissue processing techniques. Serial 4 µm slices were obtained and every tenth slide stained with haematoxylin and eosin until the portion of the block containing the vessel disk was reached. Factor VIII staining was performed to confirm that vascular endothelial cells were present in the outgrowths.
Paraffin sections of the vessel/fibrin clot were deparaffinized and incubated in 3% H 2 O 2 for 15 minutes at room temperature, washed in distilled water (dH 2 O) and placed and preheated in Antigen Retrieval® (Biogenix, San Ramon, CA) solution. Slides were microwaved for 10 minutes on medium power and left in sealed container for 15 minutes, followed by washing in dH 2 O 3 times and then in OptiMax Wash Buffer® (Biogenix). Slides were incubated in PeroxiDaze 1® (Biocare Medical, Walnut Creek, CA) for 15 minutes at room temperature, again washed in OptiMax buffer, and incubated in Power Block® (Biogenix, San Ramon, CA) for 10 minutes. A 1:1000 dilution of sst 2 antiserum (or a 1:1000 dilution of preimmune serum) in diluent buffer (Biomedia, Foster City, OH) was added to separate slides and incubated at 4°C overnight. Slides were washed in OptiMax Wash Buffer® for 20 minutes at room temperature. Secondary antibody (Biogenix multilink super sensitive biotinylated antibody) was added to the sections which were incubated for 20 minutes at room temperature. Slides were rinsed in OptiMax Wash Buffer® for a minimum of 20 minutes, followed by incubation in conjugated streptavidin (Biogenix) for 20 minutes. Slides were rinsed in OptiMax Wash Buffer® for 20 minutes. AEC (3-amino-9-ethyl-carbazole) chromogen was applied for 10 to 20 minutes, followed by rinsing in OptiMax Wash Buffer® and dH 2 O. Slides were lightly counterstained with haematoxylin for 10 seconds followed by 3 seconds in ammonia water, rinsed in dH 2 O, coverslipped with Crystal mount, placed in a 60°C oven for 15 minutes and the cover slip sealed with Permount (Biogenix, San Ramon, CA).
RESULTS
Gene expression in quiescent, proliferating and nonproliferating placental vein cultures
We analysed sst 2 receptor mRNA expression in non-proliferating vein and proliferating placental vein endothelial cells obtained from 6 placentas. In each of the placental samples, we found that sst 2 gene expression was absent in non-proliferating endothelial cells but was present in the proliferating endothelium ( Figure 1A) . GAPDH mRNA was expressed in all samples ( Figure 1B) . Sst 2 gene expression was confirmed by Southern hybridization analysis of the amplified gene products derived from proliferating placental vein endothelial cells. Hybridization of the amplified gene product with a sst 2 probe revealed a single product of the expected molecular weight (Figure 2 ).
Localization of radiolabelled somatostatin analogues in angiogenic vessels in vivo
Scans and radiographs were performed in register so that we could compare relative radioligand uptake in the liver (normal route of excretion) ( Figure 3A ) and in the tumour ( Figure 3B ). These scans revealed significant radioligand uptake in the SKNSH tumour even though the tumour cells do not express somatostatin receptors. Alternatively, normal (non-proliferating) blood vessels in non-tumour-bearing sites did not accumulate the radioligand, implying that binding of the radioligand in the tumour was due to sst 2 receptor expression on the angiogenic blood vessels supplying the tumour.
Immunohistochemical staining of vein disks
To confirm the endothelial nature of the sprouts from the vein disks, factor VIII, staining was performed (Figure 4 ). Immunohistochemical staining for sst 2 receptors revealed the presence of the receptor protein on cells forming the vascular sprouts ( Figure 5 ). The vein disk did not stain for sst 2 receptors except at the periphery of the disk, the origin of the neovascular sprouts. This staining pattern was not seen in the non-angiogenic disks incubated in the anti-sst 2 antiserum (not shown). Neither the angiogenic nor the non-angiogenic vein disks exhibited staining following incubation in the nonimmune serum (Figure 6 ). Previous work with this A N A Figure 2 Southern hybridization of the RT-PCR product shown in Figure 1 with an sst 2 probe demonstrates a single product of the appropriate molecular weight in the mRNA from the angiogenic (A), but not in the mRNA from the non-angiogenic (NA) vein disk antibody demonstrated sst 2 staining on the endothelial cells of peritumoral vessels in a mouse tumour xenograft model. Absorption of the sst 2 antibody with sst 2 antigen ablated the immunohistochemical staining of the peritumoral vessels (Albers et al, 2000) .
DISCUSSION
We have previously demonstrated in both the chicken chorioallantoic membrane (CAM) assays and the rabbit bFGF-induced corneal micropocket angiogenesis models that octreotide acetate will inhibit angiogenesis (Woltering et al, 1991; Barrie et al, 1993; Patel et al, 1994; Conway et al, 1996) . This inhibition is proportional to a somatostatin analogue's ability to inhibit growth hormone which in turn is proportional to the analogue's binding affinity for sst 2 (Woltering et al, 1997) . Inhibition of angiogenesis in the CAM model is G-protein-, adenylate cyclase-, and calciumdependent similar to somatostatin inhibition of peptide release from neuroendocrine cells (Patel et al, 1994) . Based on these observations, it appears that similar receptors and post-receptor signal transduction pathways are responsible for somatostatin's ability to inhibit peptide release, tumour growth, and angiogenesis (Bhatena et al, 1981; Thompson et al, 1986; Woltering et al, 1986; Wynick and Bloom, 1991) . The widespread use of radiolabelled somatostatin analogues in patients with neuroendocrine tumours has demonstrated that these sst 2-containing tumours avidly bind radiolabelled sst 2-preferring somatostatin analogues such as tyr 3 -octreotide, lanreotide, and pentetreotide (Schirmer et al, 1993; Woltering et al, 1994; Martinez et al, 1995; Woltering et al, 1995; McCarthy et al, 1998; Cuntz et al, 1999; Espenan et al, 1999) . Inevitably, as larger numbers of tumour-bearing patients have been scanned with these radiolabelled analogues, tissues and organs subjected to nontumour disease processes have been shown to bind these radioligands. In a study by van Hagen et al, 111 In-pentetreotide localized to joints actively involved in rheumatoid disease (van Hagen et al, 1994) . This is in contrast to a lack of binding seen in osteoarthritic joints. One of the prominent features of rheumatoid arthritis is the development of a vascular pannus in the active rheumatoid joint, a feature absent in normal joints, quiescent rheumatoid joints, and osteoarthritis joints. Vascularization of the rheumatoid joint is felt to contribute to joint destruction seen in rheumatoid arthritis. Localization of pentetreotide to the active rheumatoid, vascularized joint is consistent with our observation that neovessel formation is associated with expression of sst 2.
Several authors have demonstrated that radiolabelled sst 2-preferring somatostatin analogues will bind to a variety of tumour cell types, including breast cancer, endocrine tumours, renal cell carcinomas, melanomas, neuroblastomas, medulloblastomas, high-grade gliomas, high-grade lymphomas, meningiomas, Merkel cell tumours, and small cell carcinomas of the lung (Woltering et al, 1995) . More recently, others have demonstrated Figure 3 (A) Scintographs and radiographs were performed in register to compare relative radioligand uptake in the liver (normal route of excretion). The SKNSH tumour (sst 2-negative) shows intense uptake of a radiolabelled sst 2-preferring somatostatin analogue. (B) Scintographs and radiographs were performed in register to compare relative radioligand uptake in the tumour. The SKNSH tumour (sst 2-negative) shows intense uptake of a radiolabelled sst 2-preferring somatostatin analogue that prostate cancers will selectively bind radiolabelled somatostatin analogues, however, the level of binding is less than that seen in endocrine neoplasms (Nilsson et al, 1995; Kalkner et al, 1998) . Other tumours have been imaged with radiolabelled analogues and in many instances subsequent evaluation of these tumours by autoradiography shows little or no uptake or binding of the radiolabelled analogue by tumour cells. We believe that radiolabelled analogue binding to tumour-associated angiogenic blood vessels may explain tumour imaging in sst 2-negative tumours. In almost all tumour types, high-grade lesions have more intense ligand binding than low-grade lesions, an observation consistent with a poorly differentiated tumour developing a more intense angiogenic response.
These findings may have considerable clinical relevance. An angiogenic response is required for a tumour to grow beyond a diameter of 2 mm. The expression of sst 2 in angiogenic vessels implies that tumours greater than 2 mm in diameter might bind sst 2-preferring radiolabelled somatostatin analogues either to their tumour cells, their angiogenic neovessels, or both. This observation provides encouragement for the development of specific sst 2 targeted therapy in tumours with homogeneous or heterogeneous receptor distribution.
Other investigators have noted that tumour cell expression of sst 2 is heterogeneous and that radiolabelled somatostatin analogue therapy is best accomplished by the use of high-energy radioisotopes (Bootsma et al, 1993) . While the heterogeneous expression of sst 2 on tumour cells is ubiquitous, it appears that all proliferative neovessels homogeneously express this receptor. This difference in receptor expression may permit the use of low energy radioisotopes for therapy (McCarthy et al, 1998; Espenan et al, 1999) . Sst 2-targeted applications may include intraoperative gamma localization of occult primary tumours, and intraoperative gamma detection of microscopically positive primary tumour resection margins (Schirmer et al, 1993; Woltering et al, 1994; Martinez et al, 1995; Cuntz et al, 1999) . This sensitive technique may also allow the detection of small deposits of tumour in lymph nodes or in areas outside the normal field of resection . Other applications of sst 2-targeted techniques include external scintigraphic imaging and in situ radiotherapy. Recent reports on the use of low energy Auger electron emitters, such as
111
In pentetreotide for therapy of sst 2-expressing tumours are encouraging (McCarthy et al, 1998; Espenan et al, 1999) . Others have used high-energy radiolabelled somatostatin analogues for therapy, hoping that higher energy radioisotopes will induce cell death in adjacent receptor-negative cells (Zamora et al, 1997; Espenan et al, 1999) . Somatostatin analogues can also be conjugated to chemotherapeutic agents or toxins and may provide highly targeted tumoricidal or angiocidal therapy (Plownoski et al, 2000) .
The results of this study reveal that sst 2 expression occurs when vascular endothelial cells begin to grow. The finding paves the way for the development of a highly specific target for anti-angiogenic therapy using sst 2-preferring somatostatin analogues.
